Trial Profile

STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atorvastatin (Primary)
Indications Heart failure
Focus Therapeutic Use
Acronyms STOP-CA

Most Recent Events

01 Jun 2024 Results of subgroup analysis assessing the impact of atorvastatin on efficacy in patients with diffuse large B-cell lymphoma published in the Leukemia and Lymphoma
29 Nov 2023 Status changed from active, no longer recruiting to completed.
08 Aug 2023 Primary endpoint has been met. (Left ventricular Ejection Fraction (LVEF))

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com